

## IPSOGEN expands its U.S. presence through licensing agreement with Quest Diagnostics

**Marseille, France, October 6<sup>th</sup>, 2008** - Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemia, today announced a non-exclusive license agreement with Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests. Additional terms were not disclosed.

### About IPSOGEN

Ipsogen, Cancer Profiler, develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists decisions along their complex therapeutic path.

With more than 60 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that remained unavailable until now.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society.

Ipsogen employed 40 people as of April 30, 2008. Its headquarters are located in Marseilles, France. The company has also a subsidiary, Ipsogen Inc., in New Haven, CT, USA.

For more information, visit: [www.ipsogen.com](http://www.ipsogen.com)

### Contacts

#### IPSOGEN

**Vincent Fert**

President and CEO  
Tel.: + 33 (0)4 9129 3090  
[fert@ipsogen.com](mailto:fert@ipsogen.com)

**Suzan Hertzberg**

President Ipsogen Inc. and VP CBD  
Tel.: +1 (203) 285-6170  
[hertzberg@ipsogen.com](mailto:hertzberg@ipsogen.com)

**Stanislas Piot**

CFO  
Tel.: + 33 (0)4 9129 3090  
[piot@ipsogen.com](mailto:piot@ipsogen.com)

**ATCG Press****Corporate and Product  
Information**

Marielle Bricman  
Tel.: + 33 (0)4 9125 0785

[ipsogen@atcg-partners.com](mailto:ipsogen@atcg-partners.com)

**NewCap****Financial Communication and  
Investor Relations**

Axelle Vuillermet & Pierre Laurent  
Tel.: + 33 (0)1 44 71 94 93

[ipsogen@newcap.fr](mailto:ipsogen@newcap.fr)